The newborn mouse is relatively immuno-incompetent and potentially susceptible to tolerance to allogeneic cells. As a prelude to assessing the effects of monoclonal antibody (MoAb) on newborn ...

Cytotoxic T lymphocytes and natural killer cells are essential effectors of ... with the YTS 169 monoclonal antibody used for in vivo depletion. Fisher's exact method was used to interpret the ...

Novartis got in on the action last year, paying an undisclosed amount to leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy ...

MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity ...

ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells ... cell depletion, typically taking weeks. By engineering immune cells directly ...